These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 32747369)

  • 1. Same Name, Different Game: EGFR Drives Intrinsic KRAS
    Koleilat MK; Kwong LN
    Cancer Discov; 2020 Aug; 10(8):1094-1096. PubMed ID: 32747369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EGFR Blockade Reverts Resistance to KRAS
    Amodio V; Yaeger R; Arcella P; Cancelliere C; Lamba S; Lorenzato A; Arena S; Montone M; Mussolin B; Bian Y; Whaley A; Pinnelli M; Murciano-Goroff YR; Vakiani E; Valeri N; Liao WL; Bhalkikar A; Thyparambil S; Zhao HY; de Stanchina E; Marsoni S; Siena S; Bertotti A; Trusolino L; Li BT; Rosen N; Di Nicolantonio F; Bardelli A; Misale S
    Cancer Discov; 2020 Aug; 10(8):1129-1139. PubMed ID: 32430388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KRAS G12C Inhibitors in the Treatment of Metastatic Colorectal Cancer.
    Xiao A; Fakih M
    Clin Colorectal Cancer; 2024 Sep; 23(3):199-206. PubMed ID: 38825433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacious Combination Drug Treatment for Colorectal Cancer That Overcomes Resistance to KRAS G12C Inhibitors.
    Matsubara H; Miyoshi H; Kakizaki F; Morimoto T; Kawada K; Yamamoto T; Obama K; Sakai Y; Taketo MM
    Mol Cancer Ther; 2023 Apr; 22(4):529-538. PubMed ID: 36780229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer.
    Araujo LH; Souza BM; Leite LR; Parma SAF; Lopes NP; Malta FSV; Freire MCM
    BMC Cancer; 2021 Feb; 21(1):193. PubMed ID: 33632153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines.
    Vitiello PP; Cardone C; Martini G; Ciardiello D; Belli V; Matrone N; Barra G; Napolitano S; Della Corte C; Turano M; Furia M; Troiani T; Morgillo F; De Vita F; Ciardiello F; Martinelli E
    J Exp Clin Cancer Res; 2019 Jan; 38(1):41. PubMed ID: 30691487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative Systems Pharmacology Analysis of KRAS G12C Covalent Inhibitors.
    Stites EC; Shaw AS
    CPT Pharmacometrics Syst Pharmacol; 2018 May; 7(5):342-351. PubMed ID: 29484842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The gRASs Is Greener: Potential New Therapies in Lung Cancer with Acquired Resistance to KRAS
    Pinnelli M; Trusolino L
    Cancer Discov; 2021 Aug; 11(8):1874-1876. PubMed ID: 34344756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Remodeling of the tumor/tumor microenvironment ecosystem during KRAS G12C inhibitor clinical resistance in lung cancer.
    Manabe T; Bivona TG
    J Clin Invest; 2022 Feb; 132(4):. PubMed ID: 35166243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KRAS-G12C covalent inhibitors: A game changer in the scene of cancer therapies.
    Naim N; Moukheiber S; Daou S; Kourie HR
    Crit Rev Oncol Hematol; 2021 Dec; 168():103524. PubMed ID: 34800654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KRAS G12C inhibition with sotorasib in metastatic colorectal cancer.
    Severi C; Van Cutsem E
    Ann Palliat Med; 2022 Aug; 11(8):2792-2795. PubMed ID: 35989651
    [No Abstract]   [Full Text] [Related]  

  • 12. KRAS
    Kyriakopoulos G; Katopodi V; Skeparnias I; Kaliatsi EG; Grafanaki K; Stathopoulos C
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-Metastatic Activity of an Anti-EGFR Monoclonal Antibody against Metastatic Colorectal Cancer with
    Ohishi T; Kato Y; Kaneko MK; Ohba SI; Inoue H; Harakawa A; Kawada M
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32839411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting KRAS in Colorectal Cancer.
    Wang C; Fakih M
    Curr Oncol Rep; 2021 Feb; 23(3):28. PubMed ID: 33582927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA-425-5p Expression Affects BRAF/RAS/MAPK Pathways In Colorectal Cancers.
    Angius A; Pira G; Scanu AM; Uva P; Sotgiu G; Saderi L; Manca A; Serra C; Uleri E; Piu C; Caocci M; Ibba G; Zinellu A; Cesaraccio MR; Sanges F; Muroni MR; Dolei A; Cossu-Rocca P; De Miglio MR
    Int J Med Sci; 2019; 16(11):1480-1491. PubMed ID: 31673240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term survival with erlotinib in advanced lung adenocarcinoma harboring synchronous EGFR G719S and KRAS G12C mutations.
    Ricciuti B; Baglivo S; Ludovini V; Sidoni A; Metro G; Brambilla M; Siggillino A; Reda MS; Rebonato A; Maiettini D; Chiari R
    Lung Cancer; 2018 Jun; 120():70-74. PubMed ID: 29748019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Promising Therapeutic Efficacy of GC1118, an Anti-EGFR Antibody, against KRAS Mutation-Driven Colorectal Cancer Patient-Derived Xenografts.
    Lee HW; Son E; Lee K; Lee Y; Kim Y; Lee JC; Lim Y; Hur M; Kim D; Nam DH
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31771279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging RAS, BRAF, and EGFR mutations in cell-free DNA of metastatic colorectal patients are associated with both primary and secondary resistance to first-line anti-EGFR therapy.
    Yamada T; Matsuda A; Takahashi G; Iwai T; Takeda K; Ueda K; Kuriyama S; Koizumi M; Shinji S; Yokoyama Y; Ohta R; Yoshida H
    Int J Clin Oncol; 2020 Aug; 25(8):1523-1532. PubMed ID: 32394048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KRAS and 2 rare PI3KCA mutations coexisting in a metastatic colorectal cancer patient with aggressive and resistant disease.
    Tessitore A; Bruera G; Mastroiaco V; Cannita K; Cortellini A; Cocciolone V; Dal Mas A; Calvisi G; Zazzeroni F; Ficorella C; Ricevuto E; Alesse E
    Hum Pathol; 2018 Apr; 74():178-182. PubMed ID: 29409955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KRAS mutation testing of colorectal cancer for anti-EGFR therapy: dogmas versus evidence.
    Tímár J; Hegedüs B; Rásó E
    Curr Cancer Drug Targets; 2010 Dec; 10(8):813-23. PubMed ID: 20718705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.